Namenda
Intended to target cognitive decline in Alzheimer's disease, this medication is designed to support mental function and alleviate symptoms of moderate to severe dementia.
Strengths: 5 · 10mg
Where to Check Availability
Medicine details
- Conditions
- Alternative names
Ebixa
- Therapeutic class
NMDA Receptor Antagonist
- Pharmacological class
Adamantane Derivative
- Contraindications
hypersensitivity to memantine
- Precautions and warnings
use with caution in renal impairment; monitor patients with epilepsy
- Minor side effects
dizziness; headache; constipation; somnolence
- Moderate side effects
hypertension; confusion; gait disturbance
- Dosage forms
Film-coated tablet
- Administration route
Oral use
- Prescription status
POM
- Manufacturer
Merz Pharmaceuticals
- Onset Time
2–4 weeks
- Duration
Indefinite therapy
- Storage instructions
Store in a cool, dry place.
- Drug interactions
amantadine; ketamine; dextromethorphan
- Age restrictions
Not for paediatric use.
Serious side effects
psychosis — requires immediate medical attention; seizures — requires immediate medical attention
Patient summary
Intended to target cognitive decline in Alzheimer's disease, this medication is designed to support mental function and alleviate symptoms of moderate to severe dementia.
Mechanism of action
Memantine acts as an uncompetitive antagonist of NMDA receptors in the central nervous system. It mitigates the effects of pathologically elevated glutamate levels which can contribute to neurodegeneration.
Pregnancy and breastfeeding
Pregnancy: Not recommended if benefit does not outweigh risk. Breastfeeding: Not recommended.
Namenda
Intended to target cognitive decline in Alzheimer’s disease, this medication is designed to support mental function and alleviate symptoms of moderate to severe dementia.
Editorial Notes
- Active ingredient(s): Memantine
- Listed indication(s): Alzheimer’s Disease
Usually available as
- 180 tablets - 5 mg140-5-mg-15566
- 180 tablets - 10 mg140-10-mg-15562